Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

NCT07120698 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

115

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)
MRD
II-IIIB Stages
Adjuvant Immunotherapy

Interventions

DRUG: Sintilimab

Sponsor

Guangdong Association of Clinical Trials

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]